Reviva Pharmaceuticals (NASDAQ: RVPH ) looks to improve the standard of care treatment for schizophrenia, and is well underway to do so. The FDA requires two well-controlled trials and long-term data for that purpose. Reviva has already presented goodI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cove ...

Exhibit 99.1 Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – Cupertino, Calif., November 14, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Revi ...

– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies t ...

Fair Value of Warrant Liabilities - Fair value of warrant liabilities as of September 30, 2024: $77,884, compared to $806,655 as of December 31, 2023[97] - Change in fair value of warrant liabilities for the nine months ended September 30, 2024: $(728,771), compared to $305,972 for the same period in 2023[97] Lattice Model Parameters - Risk-free interest rate used in Lattice model: 3.91% as of September 30, 2024, compared to 4.25% as of December 31, 2023[98] - Remaining expected term of Private Warrants: 1.21 years as of September 30, 2024, compared to 1.96 years as of December 31, 2023[98] - Expected volatility used in Lattice model: 123.60% as of September 30, 2024, compared to 89.00% as of December 31, 2023[98] - Stock price on valuation date: $1.44 as of September 30, 2024, compared to $5.15 as of December 31, 2023[98] - Exercise price of Private Warrants: $11.50 as of September 30, 2024 and December 31, 2023[98] Stock Options and Vesting - Grant of 730,000 nonqualified stock options to non-executive employees on October 30, 2024, with an exercise price of $1.16[99] - Vesting periods for granted stock options range from sixteen months to thirty-eight months[99] Market Risk Disclosures - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[175]

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually O ...

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4306526 ...

Exhibit 99.1 Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 – – European patent granted covering brilaroxazine use for treating pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) in any patients – - U.S. patent granted covering use of brilaroxazine for the treatment ...

CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, ...

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of PH/PAH "This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven ...